+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Flow cytometric analysis of HL-60 cells using CD218A mouse mAb (green) and negative control (red).    

  
  

CD218a antibody targets the CD218a antigen, also known as interleukin-18 receptor alpha (IL-18Rα), a key component of the IL-18 receptor complex. IL-18 is a pro-inflammatory cytokine involved in innate and adaptive immunity, particularly in promoting Th1 cell responses and NK cell activity. The IL-18Rα subunit binds IL-18 with low affinity, requiring association with the β-chain (CD218b/IL-18Rβ) to form a high-affinity signaling receptor. CD218a is expressed on immune cells, including T cells, NK cells, macrophages, and dendritic cells, and its activation triggers downstream pathways like NF-κB and MAPK, driving inflammatory responses.

CD218a antibodies are essential tools in studying IL-18 signaling mechanisms, receptor expression patterns, and dysregulation in diseases such as autoimmune disorders, chronic inflammation, and cancer. They are used in techniques like flow cytometry, Western blotting, and immunohistochemistry to detect receptor presence or block IL-18 interactions. Research using these antibodies has highlighted IL-18Rα's role in pathologies like rheumatoid arthritis, inflammatory bowel disease, and sepsis, making it a potential therapeutic target. Monoclonal anti-CD218a antibodies are also explored for therapeutic applications to modulate excessive inflammation. Understanding CD218a's function through antibody-based studies continues to advance insights into immune regulation and therapeutic intervention strategies.